• I-BET151 (GSK1210151A): Technical Guidance for Cancer Assays

  2026-06-19

  I-BET151 (GSK1210151A) enables precise inhibition of BET bromodomains, supporting research on gene regulation and oncogenic pathways in cancer biology. It is best suited for cell-based and xenograft studies targeting BRD2, BRD3, and BRD4, but should not be used for diagnostic or therapeutic purposes. Researchers must follow solubility and storage recommendations to ensure reproducible results.

• iPSC-Derived Airway Models Advance Cystic Fibrosis Drug Test

  2026-06-19

  This study introduces a multimodal platform using patient-derived iPSC airway epithelial cells to model cystic fibrosis (CF) across diverse CFTR variants. By adapting functional assays to these advanced models, researchers can better evaluate genotype-specific responses to CFTR modulators, accelerating therapeutic discovery for rare CF subtypes.

• Doxycycline Hyclate: Strategic MMP Inhibition in Neurovascul

  2026-06-18

  Doxycycline hyclate, a semisynthetic tetracycline derivative, is emerging as a powerful matrix metalloproteinases inhibitor with broad translational potential in neurovascular research. This article synthesizes the latest mechanistic findings, including evidence from arsenic-induced cognitive impairment studies, to provide strategic guidance for translational researchers. By contextualizing recent in vivo data, protocol pointers, and the evolving competitive landscape, we highlight the opportunities and boundaries for deploying doxycycline hyclate in addressing blood-brain barrier (BBB) disruption, neurotoxicity, and beyond.

• RNAi Screen Reveals Vesicular Transport in SARS-CoV-2 Releas

  2026-06-18

  Kerr et al. present an arrayed RNA interference screen that uncovers the critical role of host vesicular transport factors, particularly Rab11a-mediated cargo delivery, in the assembly and release of SARS-CoV-2. Their work highlights new host-targeting antiviral strategies and demonstrates the utility of CDK9 inhibition in disrupting viral egress.

• Targeting BLM Helicase: ML216 and the New Era of Synthetic L

  2026-06-17

  Explore how ML216, a potent BLM helicase inhibitor, advances synthetic lethality strategies in DNA repair-deficient cancers. This thought-leadership article synthesizes mechanistic insight, translational strategy, and competitive positioning, drawing on breakthrough studies in the field. It offers guidance for researchers seeking to leverage ML216 in the development of next-generation targeted cancer therapies.

• Promethazine HCl: Evidence-Based Applications in Immunology

  2026-06-17

  Promethazine HCl is a phenothiazine derivative and selective H1 receptor antagonist. It enhances macrophage antibacterial activity through ROS and autophagy induction, providing a validated tool for GPCR signaling and inflammation research. APExBIO supplies this compound in high-purity formats for reproducible scientific workflows.

• SAR405 Vps34 Inhibitor: Precision Tools for Autophagy Resear

  2026-06-16

  SAR405, a highly selective Vps34 inhibitor from APExBIO, enables unparalleled control over autophagy inhibition and vesicle trafficking modulation in disease models. This article provides stepwise protocols, troubleshooting expertise, and new experimental strategies inspired by paradigm-shifting findings on AMPK-ULK1-Vps34 signaling.

• Doxorubicin in Cancer Research: Optimized Workflows & Troubl

  2026-06-16

  Doxorubicin (Adriamycin) stands as a gold-standard chemotherapeutic for dissecting DNA damage responses and overcoming resistance in both hematologic and solid tumor models. This guide translates cutting-edge reference findings into step-wise protocols and troubleshooting tips, ensuring reproducibility and maximal insight for oncology researchers.

• Lypressin Acetate: Pharmacological Precision and Emerging An

  2026-06-15

  Unlock the unique pharmacological profile of Lypressin acetate, a potent lysine vasopressin analog, and discover how its distinct mechanism and evolving antiviral potential set it apart in both clinical and experimental research.

• X-Gal in Molecular Cloning: Applied Workflows and Troublesho

  2026-06-15

  X-Gal (5-bromo-4-chloro-indolyl-β-D-galactopyranoside) empowers scientists to distinguish recombinant colonies with speed and clarity in blue-white screening workflows. This guide delivers actionable protocol insights, advanced assay applications, and troubleshooting strategies, grounded in current research and best practices for reliable, high-sensitivity detection.

• Geneticin (G-418 Sulfate): Precision Selection and Ribosomal

  2026-06-14

  Explore how Geneticin (G-418 Sulfate) uniquely leverages its ribosomal protein synthesis inhibition pathway for advanced genetic engineering and antiviral applications. This article provides a deeper mechanistic perspective and practical assay guidance beyond standard protocols.

• MK-1775 (Wee1 Kinase Inhibitor): Precision Tools for Cell Cy

  2026-06-13

  Explore how MK-1775, a potent Wee1 kinase inhibitor, enables nuanced cell cycle checkpoint abrogation and advanced cancer research workflows. This article offers new insights into in vitro evaluation strategies and practical assay design.

• ML216, BLM Helicase Inhibitor: Precision in DNA Repair Resea

  2026-06-12

  ML216 offers researchers a selective, potent tool to dissect DNA repair via BLM helicase inhibition, unlocking insights into synthetic lethality and tumor cell sensitization. This article details advanced workflows, real-world troubleshooting, and the latest translational findings—empowering your lab to leverage ML216 for cutting-edge oncology and genome stability studies.

• Injectable Hemostatic GelMA/QCS/Ca2+ Adhesive for Rapid Blee

  2026-06-12

  This study introduces a blue light-activated GelMA/QCS/Ca2+ hemostatic adhesive designed for fast control of non-compressible hemorrhage and prevention of wound infection. Its dual-network composition delivers superior mechanical strength, tissue adhesion, and antibacterial properties, offering a significant advance over conventional wound dressings.

• Dinaciclib Synthetic Lethality Targets VHL-Deficient Renal C

  2026-06-11

  This study demonstrates that the cyclin-dependent kinase inhibitor Dinaciclib selectively induces cell death in VHL-deficient clear cell renal cell carcinoma (CC-RCC) via synthetic lethality. The findings reveal a promising therapeutic strategy for targeting CC-RCC with improved specificity and a favorable therapeutic window.

11452 records 1/764 page Next 12345 下5页 Last page